Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab
Ilic I et al. - In a trial to determine the influence of germinal-center B-cell (GCB) and non-GCB phenotypes of diffuse large B-cell lymphoma (DLBCL) on outcome of 92 pts treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy, with or without rituximab, it was shown that pts with immunohistochemically determined GCB-type DLBCL did not have an improved prognosis, irrespective of whether they had received rituximab or not. Methods- The differentiation between GCB and non-GCB types was arrived at by immunohistochemistry using previously published criteria.
- 39 pts had the GCB and 53 had the non-GCB type of DLBCL.
Results- 49 pts were treated with rituximab and chemotherapy; 43 were treated with chemotherapy alone.
- The GCB and non-GCB group did not differ in their international prognostic index factors and score, presence of bulky disease, or frequency of rituximab treatment.
- Median follow-up of surviving pts was carried out for 37 mos.
- There was no difference between GCB and non-GCB groups in both overall response rates (67 vs 70%, respectively) and estimated rates of 3-yr event-free (46 vs 49%, respectively) and overall (54 vs 56%, respectively) survival.
- No differences of the outcomes were observed between subgroups treated with or without rituximab.
[more...]
|
|
|
